News | EU Patents Matter

EU court limits pharma's scope for patent extensions22 Mar 2019
Supplementary protection certificates (SPCs) are not available for formulations of medicines that contain substances previously authorised for use in the EU, the EU's highest court has ruled.
Brexit a factor in patents court reference to CJEU5 Mar 2019
The UK's impending exit from the EU was a leading factor in a High Court judge's recent decision to seek immediate clarity from the EU's highest court on how to interpret EU intellectual property (IP) laws concerning supplementary protection certificates (SPCs).
Export manufacturing waiver moves closer21 Feb 2019
EU law makers have agreed to update intellectual property (IP) laws to allow European manufacturers of generic and biosimilar medicines to better compete in global markets, but a body representing some of Ireland's biggest pharmaceutical companies has said the proposals could undermine investment in...
'Internet of things' spurs broad interest in standard essential patent licensing4 Feb 2019
ANALYSIS: A push to set new principles around the licensing of standard-essential patents highlights the growing number of businesses whose operations, products and services now rely on standardised technology.
Biologics and biosimilars: competition law tipped to shape market31 Jan 2019
Manufacturers of biological medicines, or 'biologics', in Europe must consider how competition law might impact the way they market their products and enforce their patent rights throughout the lifetime of their products, experts in intellectual property (IP) and competition law at international law...
Generics closer to gaining new EU manufacturing waiver18 Jan 2019
Plans to give generic drugs companies more freedom to manufacture new medicines in the EU more quickly moved closer to becoming law after they were endorsed by an EU law-making body earlier this week.